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Abstract
Background: Isoprenoids are the most diverse and abundant group of natural products. In Plasmodium falciparum,
isoprenoid synthesis proceeds through the methyl erythritol diphosphate pathway and the products are further
metabolized by farnesyl diphosphate synthase (FPPS), turning this enzyme into a key branch point of the
isoprenoid synthesis. Changes in FPPS activity could alter the flux of isoprenoid compounds downstream of FPPS
and, hence, play a central role in the regulation of a number of essential functions in Plasmodium parasites.
Methods: The isolation and cloning of gene PF3D7_18400 was done by amplification from cDNA from mixed
stage parasites of P. falciparum. After sequencing, the fragment was subcloned in pGEX2T for recombinant protein
expression. To verify if the PF3D7_1128400 gene encodes a functional rPfFPPS protein, its catalytic activity was
assessed using the substrate [4-14C] isopentenyl diphosphate and three different allylic substrates: dimethylallyl
diphosphate, geranyl diphosphate or farnesyl diphosphate. The reaction products were identified by thin layer
chromatography and reverse phase high-performance liquid chromatography. To confirm the product spectrum
formed of rPfFPPS, isoprenic compounds were also identified by mass spectrometry. Apparent kinetic constants KM
and Vmax for each substrate were determined by Michaelis–Menten; also, inhibition assays were performed using
risedronate.
Results: The expressed protein of P. falciparum FPPS (rPfFPPS) catalyzes the synthesis of farnesyl diphosphate, as
well as geranylgeranyl diphosphate, being therefore a bifunctional FPPS/geranylgeranyl diphosphate synthase
(GGPPS) enzyme. The apparent KM values for the substrates dimethylallyl diphosphate, geranyl diphosphate and
farnesyl diphosphate were, respectively, 68 ± 5 μM, 7.8 ± 1.3 μM and 2.06 ± 0.4 μM. The protein is expressed
constitutively in all intra-erythrocytic stages of P. falciparum, demonstrated by using transgenic parasites with a
haemagglutinin-tagged version of FPPS. Also, the present data demonstrate that the recombinant protein is
inhibited by risedronate.
Conclusions: The rPfFPPS is a bifunctional FPPS/GGPPS enzyme and the structure of products FOH and GGOH
were confirmed mass spectrometry. Plasmodial FPPS represents a potential target for the rational design of
chemotherapeutic agents to treat malaria.
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Background
Malaria is a leading cause of morbidity and mortality in
tropical regions. In 2010, there were an estimated 216
million episodes of malaria of which approximately 81%,
or 174 million cases, occurred in the African continent.
On a worldwide scale, 655,000 individuals died of mal-
aria, most of them in sub-Saharan Africa [1]. Of the five
parasite species that infect humans, Plasmodium falcip-
arum is responsible for the vast majority of severe forms
of, and deaths from, the disease. Recent observations
alert that the parasite is becoming resistant to virtually
all drugs currently used in the treatment of the disease.
Efforts to tackle this problem are based on combined
therapy using drugs to which the parasites have not
yet developed resistance, as well as identifying new
drug targets [2].
Plasmodium falciparum parasites harbour an unusual
plastid organelle called the apicoplast that has an essen-
tial role for their survival since isoprenoid precursors are
synthesized there [3]. Deletion of this organelle by con-
comitant supplementation with isopentenyl diphosphate
(IPP) proved that this is the only essential function of the
apicoplast during blood stage growth [4]. Isoprenoids are
very diverse and constitute an abundantly present group
of natural products. Synthesis of isoprenoids is intrinsic to
all organisms and leads to a vast array of metabolites with
diverse functions. Despite their structural and functional
variety, all isoprenoids derive from a common precursor,
isopentenyl diphosphate, and its isomer, dimethylallyl
diphosphate (DMAPP). Farnesyl diphosphate synthase
(FPPS), which belongs to a family of enzymes classified as
prenyltransferases, catalyzes the consecutive head-to-tail
condensation of IPP with DMAPP to form geranyl di-
phosphate (GPP), and then a second condensation be-
tween GPP and IPP to form farnesyl diphosphate
(FPP). FPP serves as a substrate for the first reaction
of several branched pathways leading to the synthesis
of compounds such as ubiquinone, dolichol, mena-
quinone, and prenylated proteins. FPP can also be
condensed with an additional IPP by geranylgeranyl
diphosphate synthase (GGPPS) to form geranylgeranyl
diphosphate (GGPP), which is also employed in pro-
tein prenylation and is related to carotenoid biosyn-
thesis (Figure 1).
The essential and major biosynthetic step in the me-
tabolism of all isoprenoid is the elongation of isoprene
units by prenyltransferases. These enzymes, which
subsequently mediate alkylation of IPP by allylic di-
phosphate, are classified according to the chain length
of the final product and stereochemistry of the double
bond formed by condensations. FPPS and GGPPS are
the most studied prenyltransferases and have been de-
scribed in various organisms of all three kingdoms,
Eukarya, Bacteria, and Archaea [5]. In protist para-
sites, the FPPS gene was cloned from Trypanosoma
cruzi [6], Trypanosoma brucei [7] and Toxoplasma
gondii [8]. Recently, a GGPPS from Plasmodium vivax
was described [9]. However, the first characterization
Figure 1 Schematic diagram of the isoprenoid biosynthesis and downstream products in Plasmodium falciparum. Bisphosphonates are
known to inhibit FPPS/GGPPS, thereby preventing the synthesis of FPP and GGPP required for the biosynthesis of ubiquinone, dolichol,
carotenoids, menaquinone, tocopherol, and protein prenylation. MEP: methyl erythritol phosphate.
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of a prenyltransferase in a malaria parasite was the
characterization of the octaprenyl diphosphate synthase
(OPPS) that catalyzes the condensation of FPP with IPP
to produce octaprenyl diphosphate [10].
Human FPPS has been found to be a target for
nitrogen-containing bisphosphonate (N-BP) drugs [11].
Based on “growth-rescue” and enzyme inhibition experi-
ments, human GGPPS was shown to be a major target
for the lipophilic analogues zolendronate and risedronate
[12]. These reports have generated considerable interest
in FPPS as a promising target for new anti-malarial drug
development. Jordão et al. suggested the possible
mechanism of action for risedronate in P. falciparum
by inhibition of FPPS [13]. In the causative agent of
sleeping sickness, T. brucei, the inhibition of FPPS
showed that this enzyme is essential for parasite sur-
vival [7]. Considering that FPPS is a key enzyme of
the biosynthesis of compounds already characterized
in the parasite, such as dolichols, farnesylated pro-
teins, and other final isoprenoid products [14], it is es-
sential to characterize the FPPS from P. falciparum in
order to establish an appropriate strategy for the de-
velopment of specific inhibitors.
This work describes the cloning, expression and
characterization of recombinant P. falciparum FPPS
(rPfFPPS), with catalytic activity for DMAPP, GPP, and
FPP as substrates, yielding FPP and GGPP as final prod-
ucts. Apparent kinetic parameters for the recombinant
enzyme are presented, as well as IC50 and apparent Ki
values for risedronate inhibition of rPfFPPS enzyme ac-
tivity. Constitutive protein expression is also described.
Methods
Plasmodium falciparum culture
Cultures of P. falciparum clone 3D7 were grown as
described [15], replacing human serum with Albumax
I (0.5%, Invitrogen/Life Technologies) [16]. Parasite
development and multiplication were monitored by
microscopic evaluation of Giemsa-stained thin smears.
Schizont stages were purified with magnetic columns
(MACS Separation Columns “CS”, Miltenyi Biotec)
[17]. Column pre-equilibration, washing and elution
were all carried out at room temperature with RPMI-
1640 (Sigma-Aldrich). For schizont purification, the
culture was centrifuged (2,000 x g for 5 min), the pel-
let resuspended in RMPI-1640 (1:10; v/v), 10 ml of
the 10% suspension of erythrocytes were applied to a
CS column assembled in a magnetic unit, where only
schizonts are retained. After washing the column with
50 ml of RMPI-1640, the column was removed from
the magnetic field and its contents eluted with 50 ml
of RMPI-1640 and the schizont stage parasites were
centrifuged at 2,000 × g for 5 min at room
temperature. The supernatant was discarded, and the
pellet of parasites was stored in liquid N2 for subse-
quent analysis.
Isolation and cloning of gene PF3D7_1128400
A 1,131 bp fragment of the PfFPPS gene (PlasmoDB ID
PF3D7_1128400) was amplified from cDNA from mixed
stage parasites using primers (Invitrogen/Life technologies)
PfFPPS1 (5′-CCGGATCCATGGAGAACGAGCAGAATA-
AC-3′) and PfFPPS2 (5′-CGGAATTCTCAAGCGCCTG-
TAAACAAAATGTC-3′) and the amplicon cloned in
pGEM T easy (Promega). After sequencing, the fragment
containing the complete ORF was subcloned in
pGEX2T for recombinant protein expression using the
introduced BamHI and EcoRI sites.
Expression and Purification of rPfFPPS from Escherichia coli
Recombinant pGEX-2 T-FPPS expression vector was
used to transform Escherichia coli BL21(DE3+) pLys RIL
cells. Bacterial clones were grown in LB medium
containing 50 μg/ml ampicillin and 34 μg/ml chloram-
phenicol at 37°C in Luria Broth (Hi-media) until an OD600
of 0.6. At this time point, the expression of rPfFPPS was in-
duced with 0.2 μM isopropyl β-D-thiogalactoside at 24°C
overnight. Cells were pelleted by centrifugation and
resuspended in lysis buffer PBS/0.1% Triton X-100
pH 7.2 (v/v), 0.05 mg/ml lysozyme and 0.2 mM PMSF.
Lysis was completed by sonication (five pulses of 30 s
at 40 W, at 4°C). Recombinant proteins were then puri-
fied using glutathione sepharose beads (GE Healthcare),
following the manufacturer’s instructions. Proteins were
checked for purity by SDS-PAGE [18] and quantified by
the Bradford method [19].
Enzymatic activity assay
The catalytic activity of rPfFPPS was assayed by measur-
ing the conversion of [4-14C]IPP (56.6 mCi/mmol,
Perkin Elmer Life Sciences) to [14C] products, by two
different protocols: Protocol I - The method described
by Ling et al. [8] was used with some modifications.
Briefly, the assay mixtures contained 10 mM HEPES
buffer pH 7.4, 2 mM MgCl2, 2 mM dithiothreitol,
100 μM [4-14C]IPP, an allylic substrate (100 μM DMAPP,
30 μM GPP, or 15 μM FPP), and 500–1,000 ng of re-
combinant protein in a total volume of 100 μl. The reac-
tion was carried out at 37°C for 30 min and stopped by
addition of 10 μl of 6 M HCl. The reaction mixture was
neutralized by addition of 15 μl of 6 M NaOH. The alco-
holic products were then extracted twice with 500 μl
hexane and analysed by reverse phase thin layer chroma-
tography (RP-TLC). All non-radioactive substrates and
chemicals were from Sigma-Aldrich. Protocol II -
rPfFPPS activity was measured by a modification of the
method described by Chang et al. [20]. Final assay con-
centrations were 50 mM Tris–HCl buffer pH 7.5, 2 mM
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MgCl2, 5 mM iodoacetamide, and 500–1,000 ng of re-
combinant protein. The concentrations of allylic substrate,
DMAPP, GPP and FPP were the same as described above.
The final reaction volume was 100 μl. After pre-incubation
at 37°C for 10 min, the reaction was started by adding
50 μM [4-14C]IPP. The mixture was incubated at 37°C for
30 min and the reaction was terminated by addition of
distilled H2O and NaCl-saturated water. The diphosphate
products were then extracted twice with 500 μl of 1-
butanol saturated with NaCl-saturated water and
analysed by reverse phase high-performance liquid chro-
matography (RP- HPLC). Enzyme activity measurements
using [1-(n)-3H]FPP (15 Ci/mmol, Amersham Biosci-
ences) and IPP as substrates were also carried out.
Identification of reaction products of rPfFPPS
The alcoholic products obtained by Protocol I were
analysed by TLC on reverse phase Silica Gel 60 plates
(Merck) with acetone:H2O (6:1; v/v) [8]. The position of
the standard prenyl alcohol was visualized using iodine
vapour. Radioactivity was visualized by autoradiography
in a Storm phospho-imager. The diphosphorylated prod-
ucts that were formed following Protocol II were identi-
fied by RP-HPLC and analysed on a Phenomenex Luna
C18 column (250 mm × 4.6 mm × 5 μm) (Phenomenex)
coupled with a C18 pre-column (Phenomenex), a UV
Gilson 152/UV variable UV/visible detector at 214 nm
and an FC203B fraction collector. The software used for
data processing was the UniPoint LC™ 3.0 Software Sys-
tem. The gradient elution system used was: solvent A,
25 mM NH4HCO3, pH 8.0; solvent B, 100% (v/v) aceto-
nitrile. A linear gradient was run from 0% to 100% B
over a period of 40 min, after which 100% B was then
pumped through for an additional 5 min. Fractions were
collected in 1 ml/min intervals [21]. The resulting frac-
tions were dried, resuspended in 500 μl of liquid scintilla-
tion mixture (PerkinElmer Life Sciences) and monitored
with a Beckman 5000 β-radiation scintillation counter
(Beckman).
ESI-MS/MS investigation of the products geraniol (GOH),
farnesol (FOH) and geranylgeraniol (GGOH)
Identification of product formation by using Protocol I
with non-radioactive substrates (IPP/DMAPP) in the
presence of rPfFPPS were carried out by electrospray
ionization tandem mass spectrometry (ESI-MS/MS)
using a ion trap mass spectrometer, model LCQ™ Duo
(Thermo Scientific) coupled to a nano-HPLC system
(Ultimate, Dionex). After stopping the reaction, products
were extracted with hexane, dried in a vacuum centri-
fuge, and resuspended in 40 μl of 50% acetonitrile/0.2%
formic acid. The sample was injected (10 μl) in the
nano-probe of the spectrometer by an autosampler
(Ultimate, Dionex) at a flow rate of 2 μl/min and
analysed in the positive mode, using the following pa-
rameters: spray voltage 1.8 kV, capillary voltage 38 V,
and capillary temperature 180°C. For ESI-MS/MS,
relative collision energy of 30% (1.5 eV) was applied.
Partial purification of native PfFPPS
The partial purification of native PfFPPS was performed
only with schizont stage parasites purified by magnetic
column separation, as described above. Partial protein
purification was carried out according to Tonhosolo et
al. [10]. Protocol II was used to assay the enzymatic
reaction and the diphosphate products were analysed
by RP-HPLC, as described above.
rPfFPPS kinetic assays
For determination of apparent kinetic constants, concen-
tration of the first substrate DMAPP (0–150 μM), GPP
(0–50 μM) or FPP (0–50 μM) was varied in the presence
of a fixed concentration of [4-14C]IPP (50 μM). Enzyme
activity measurements were also carried out varying the
concentration of [4-14C]IPP (0–80 μM) in the presence
of a fixed concentration of either DMAPP (100 μM),
GPP (40 μM) or FPP (50 μM). The catalytic activity of
rPfFPPS was assayed by measuring the conversion of
[4-14C]IPP to [14C] products, as described in Protocol
I. Reaction products were extracted with hexane and
quantified by liquid scintillation counting. Apparent
kinetic constants, KM and Vmax, for each substrate
were derived from fitting the data to Michaelis-
Menten (MM, Equation 1), using SigmaPlot 10, from
Systat Software. All experiments were performed in
triplicate.
v ¼ Vmax S½ 
KM þ S½  ð1Þ
rPfFPPS inhibition assays
Inhibition assays were performed in presence of a fixed
concentration (30 μM) of one allylic substrate (GPP or
FPP) and fixed concentration (30 μM) of [4-14C]IPP, with
varying concentrations of risedronate (0.005 – 1,000 μM).
Each assay contained 500 ng of rPfFPPS in a final volume
of 100 μl. The catalytic activity of rPfFPPS was measured
by the conversion of [4-14C]IPP into [14C] products, as
described in Protocol I
The concentration of risedronate required to reduce
the fractional enzyme activity to half of its initial value
in the absence of inhibitor (IC50) was obtained from
fitting the data to Equation (2) for partial inhibition
[22], in which y is the fractional activity of the enzyme
in the presence of inhibitor at concentration [I]; y(max)
is the maximum value of y observed at [I] = 0; and
ymin is the minimum limiting value of y at high
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inhibitor concentrations. Data analysis was performed
using SigmaPlot 10 (Systat Software). Relationship be-
tween IC50 and risedronate apparent dissociation constant
(Ki) in each assay was derived according to Cheng’s and
Prusoff ’s relationship, Equation (3), for competitive inhibi-
tors [23,24], in which [S] and KM are, respectively, the
concentration of the substrate for which risedronate is a
competitive inhibitor, and this substrate MM constant. All
experiments were performed in triplicate.
y ¼ ymax−ymin
1þ I½ IC50
þ ymin ð2Þ
Ki ¼ IC50
1þ S½ KM
ð3Þ
Plasmid construction
The plasmid pTEX150-HA/Stre3 [25] containing the
epitope of heamagglutinin (HA) was digested with BglII/
PstI to release the gene pTEX150. The genomic DNA
sequence encoding the C-terminal fragment of FPPS was
PCR amplified with the oligonucleotides 5′-AGATC-
TGGTATGCAAATGGGGGGTATA and 5′-CTGCAG-
CAGCGCCTGTAAACAAAATGTC, cloned in pGEM
T-easy (Promega) and verified by sequencing. A recom-
binant clone was digested with BglII/PstI and ligated
into the pTEX150 depleted vector pTEX150-HA/Stre3
generating the plasmid pFPPs-HA.
Parasite transfection and characterization of transfectants
Parasites were transfected as previously described [26],
using the electroporation conditions established else-
where [27]. Briefly, P. falciparum 3D7 was cultured in
4% haematocrit in RPMI HEPES supplemented with
0.5% Albumax I. 2 × 107 ring stage parasites at 5-8%
parasitaemia were transfected with 150 μg of plasmid.
Transfected parasites were submitted to drug pressure
with 2.5 nM WR99210 starting on the third day of cul-
ture. Parasites were cultivated in standard conditions
until parasites re-appeared and normal growth was re-
established. The integration at the genomic FPPS locus
was forced by intermittent exposure and retrieval of
WR99210. Genomic gDNA was purified using standard
protocols [28]. The integration at the genomic locus was
checked by PCR under standard conditions using oligo-
nucleotides inside and outside the integrated locus. The
details of plasmid construction and the integration are
presented on Additional file 1.
Western blot analyses
Synchronous cultures of transfected P. falciparum were
recovered in each stage. Ring, trophozoite or schizont
stages were treated with 0.15% saponin in RPMI media
to release haemoglobin from the red blood cells. Pro-
teins were extracted with buffer: 0.05 M Tris–HCl,
pH 6.8, 10% glycerol, 2 mM EDTA, 2% SDS, 0.05%
bromophenol blue, 50 mM dithiothreitol [29] for separ-
ation by gel SDS-PAGE. The gel was then transferred to
nitrocellulose membrane (Amersham) for 1 h using a
Trans-Blot semidry electroblotter (BioRad) [30]. After
blocking, membranes were incubated with an α-HA
monoclonal antibody (1:500 dilution; Sigma-Aldrich) or
antibody controls α-PTEX150 (1:1,000) [25] or α-MSP2
(1:500) [31] for 1 h at room temperature or 14 h at 4°C.
After this, the membranes were incubated with an anti-
mouse IgG labelled secondary antibody with peroxidase
and were visualized on radiographic film using the ECL
enhanced chemiluminescence detection kit according to
the instructions of the manufacturer (GE Healthcare).
Sequence analysis of the chain length determination
region
For sequence selection, similarity searches were done
using PfFPPS as query against the full NCBI nr protein
database, using a maximum E-value cut-off of 10-10. Se-
quences with 0.5 to 1.5 times the length of the P.
falciparum's protein and those identical to others were
removed. The final set of protein sequences was aligned
using muscle 3.8.31 [32] and analysed with WebLogo
2.8.2 [33] and in-house developed scripts for amino acid
composition analysis. Based on sequence conservation, 9
alignment columns either side of the First Aspartate-
Rich Motif (FARM) were analysed and only sequences
containing the canonical DDxxD motif were kept. Ac-
cession numbers and CLD region for all sequences used
can be found in Additional file 2.
Ethical statement
This study was approved by the Ethical Committee of
the Institute of Biomedical Science of University of São
Paulo,Brazil (CEUA 140.09).
Results
Expression and purification of recombinant protein
The P. falciparum gene PF3D7_1128400 was formerly
annotated as an FPPS and is currently described as a
GGPPS according to plasmoDB. Using this sequence
as template, primers were designed to amplify
PF3D7_1128400 from total cDNA by PCR. The full
length protein was expressed as a GST fusion protein
in E. coli BL21(DE3) pLys RIL cells and purified the
protein by affinity chromatography as described in the
Methods section. The protein homogeneity was in-
ferred by SDS-PAGE followed by Coomassie Blue stain-
ing, showing that the purified GST-PfFPPS (rPfFPPS)
protein has an apparent molecular mass of ~ 70 kDa,
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(sum of 26 kDa GST and 44 kDa PfFPPS) (Additional
file 3).
Catalytic activity of rPfFPPS
To verify if the PF3D7_1128400 gene encodes a func-
tional rPfFPPS protein, its catalytic activity was assessed
using the substrate [4-14C]IPP and three different allylic
substrates DMAPP, GPP or FPP under the conditions
described above. The reaction products were identified
by TLC and RP-HPLC.
The products formed following Protocol I were
extracted with hexane, and the respective alcohols
were submitted to TLC analysis. With the substrates
[4-14C]IPP and DMAPP, bands with Rf values corre-
sponding to GOH, FOH, and GGOH were observed.
Bands with similar Rf to FOH and GGOH were
detected when [4-14C]IPP and GPP were used as sub-
strates, whereas FPP and [4-14C]IPP yielded only a
band with an Rf coincident with GGOH (Figure 2).
When the enzymatic reaction was carried without any
enzyme, no products were observed (Figure 2, lanes 2,
4 and 6). When the enzymatic reaction was carried
out with purified GST only, no products were
observed.
The diphosphorylated products formed following
Protocol II were extracted with butanol-satured water
and analysed by RP-HPLC. rPfFPPS with allylic sub-
strates [4-14C]IPP and DMAPP was able to catalyze the
synthesis of GPP, FPP, and GGPP (Figure 3A), whereas
the reaction incubated with [4-14C]IPP and GPP as
substrates led to the biosynthesis of FPP and GGPP
(Figure 3B). When [4-14C]IPP and FPP were used as sub-
strates, only GGPP synthesis was observed (Figure 3C).
Similar results were obtained when the substrates [1-
(n)-3H]FPP and IPP were incubated with the rPfFPPS
(Figure 3D). When the reaction was carried without
enzyme, no products were observed. This indicates
that major products of the reactions catalyzed by the
enzyme rPfFPPS are FPP and GGPP, with a minor
production of GPP, showing both FPPS and GGPPS
activity using two different protocols.
Identification of rPfFPPs products by ESI-MS/MS
In order to further confirm the product spectrum
formed of rPfFPPS, isoprenic compounds were also
identified by mass spectrometry. Protocol I was used
for measurements of enzyme activity with non-
radioactive substrates IPP/DMAPP, and investigated
the structures of compounds formed in the presence
of rPfFPPS by ESI-MS/MS (Figure 4). Figure 4A, C
and E present the MS/MS spectra of standards GOH,
FOH, and GGOH respectively. The fragmentation pat-
terns of the precursor ions at m/z 137, corresponding
to dehydration of GOH [M-H2O]
+, at m/z 205; corre-
sponding to the dehydration of FOH [M-H2O]
+; and
at m/z 273, corresponding to the dehydration of
GGOH [M-H2O]
+, were compared between standards
and samples. The dissociation of the precursor ion at
m/z 137 (GOH) revealed the presence of major ions
at m/z 81, 94, and 108, while the dissociation of the
precursor ion at m/z 205 (FOH) resulted in the major
ion products at m/z 121, 134, 148, and 162. GGOH
precursor ion at m/z 273 revealed the product major
ions at m/z 149, 163, 189 and 217. The molecular
identity was confirmed by comparing the ESI-MS/MS
spectrum of the ions at m/z 137, m/z 205, and m/z
273 produced by rPfFPPS (Figure 4B, D and F) with
the ESI-MS/MS spectrum of the standards (Figure 4A,
C and E), revealing the same dissociation profile.
Taken together, these results underscore that the
rPfFPPS is able to catalyze reactions that lead to
GOH, FOH, and GGOH formation.
Figure 2 Analyses by TLC of products synthesized by rPfFPPS.
The activity of rPfFPPS was measured by a 14C radioactivity assay,
utilizing [4-14C]IPP and DMAPP, GPP, or FPP as allylic substrate. The
enzymatic reactions (Protocol I) and TLC were performed as
described in the Methods section. Lane 1, [4-14C]IPP + DMAPP as
substrates; lane 3, [4-14C]IPP + GPP as substrates; lane 5, [4-14C]IPP +
FPP as substrates; lanes 2, 4 and 6 control reactions without
enzymes for reactions showed on lanes 1, 3 and 5 respectively.
Products labelled with [4-14C]IPP were visualized by a Bioscan
System 200 Imaging Scanner. The positions of geraniol (GOH),
farnesol (FOH) and geranylgeraniol (GGOH) standards are indicated
on the left. The main products detected were FOH and GGOH,
indicating that this were the major enzyme products. Ori: origin
SF: front.
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Characterization of PfFPPS activity in parasite extracts by
HPLC
In order to verify if naturally occurring PfFPPS contained
in P. falciparum extracts exert similar activities as
detected with rPfFPPS, these extracts were used in-
stead of recombinant protein. The reaction was
performed with [4-14C]IPP and DMAPP, GPP or FPP
as substrate in accordance with Protocol II. The
products were analysed by RP-HPLC. Incubation of
extracts in the presence of [4-14C]IPP and DMAPP led to
formation of GPP, FPP, and GGPP. Likewise, incubation
of [4-14C]IPP andGPP as substrates yielded FPP and
GGPP as products.Finally, only GGPP was observed
when extracts were incubated with [4-14C]IPP and
FPP (Figure 5). The extracts of parasites exhibited
both FPPS and GGPPS activity and these activities
were similar to those of the rPfFPPS protein.
Apparent kinetic parameters of rPfFPPS and IC50 of
risedronate
Apparent kinetic constants of the recombinant en-
zyme were determined using varied concentrations of
[4-14C]IPP, DMAPP, GPP, and FPP as substrates
(Additional file 4). The parameters were determined
as described in the Methods section, by measuring
the radioactivity in the hexane fraction. KM and Vmax
values for each substrate are given in Table 1.
Risedronate inhibitory activity against rPfFPS, by
specifically inhibiting the condensation of IPP with an
allylic substrate was assayed as described in the
Figure 3 RP-HPLC analysis of the product spectrum synthesized by rPfFPPS. The enzymatic reactions (Protocol II) and RP-HPLC procedure
were performed as described in the Methods section. A) [4-14C]IPP and DMAPP; B) [4-14C]IPP and GPP; C) [4-14C]IPP and FPP; D) [1-3H]FPP and IPP.
Arrows indicate the co-elution positions of isoprenoid standards. The retention times of GPP, FPP and GGPP were identified by co-injection of
commercial standards.
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Methods section. Risedronate inhibition was evaluated
using FPP/IPP and GPP/IPP as substrates (Additional
file 5), yielding, respectively, IC50 values of 1.3 ±
0.2 μM and of 10 ± 1 μM. Apparent Ki values, assum-
ing risedronate competitive inhibition towards FPP
and GPP, are equal to 0.08 μM and 1.96 μM
respectively.
Analysis of rPfFPPS expression during the intra-
erythrocytic cycle by Western blot
Extracts of parasite line that had the FPPS/GGPPS en-
zyme tagged with the HA epitope were analysed for the
presence of pFPPs-HA. Samples of protein were
extracted from parasites synchronized in three main
stages (ring, trophozoite, and schizont) and detected
with a monoclonal antibody against HA. The results in-
dicate that the enzyme FPPS is constitutively expressed
in all stages during the asexual intra-erythrocytic cycle
of P. falciparum (Figure 6). As a control of the parasite
synchronization, antibodies that recognize the constitu-
tively expressed protein pTEX150 in three stages [25],
and MSP2 [31], which is expressed only in schizont
stages, were used.
CLD region sequence analysis
The CLD regions of 452 sequences containing the ca-
nonical DDxxD FARM motif were analysed by creating a
sequence logo showing relative amino acid frequencies
(Additional files 2 and 6). There is clear predominance
of aromatic amino acids (F and Y, although never W) in
positions 4 and 5 N-terminal to the FARM (henceforth
called P4 and P5). The cysteine in P5 with F or Y in P4,
as found in Toxoplasma's bifunctional FPPS/GGPPS, is
very rare, occurring in only 6 sequences (1.33% of the
total), of various taxonomic affiliations. The P. falcip-
arum sequence (S in P5, aromatic in P4) is slightly more
common, appearing in 14 sequences (3.10%). Theileria
spp. and all plasmodia but P. vivax contain SF at those
positions; other organisms of diverse taxonomic lineages
present this same sequence arrangement. In contrast,
the other two biochemically characterized bifunctional
FPPS/GGPPS enzymes present FF (Zea mays) or FS (M.
thermoautotrophicum) at these positions, with the former
found in 174 (65.71%) of all sequences and the later
present in only 22 (4.87%). Other positions in the se-
quence logo have also shown high levels of conservation
(Additional file 2), most markedly positions 2–4 (most fre-
quently LQA), 7–8 (LV), 12–13 (IM), 16 (S), 18–21
(TRRG), and 23 (P).
Discussion
FPPS is a key enzyme in the metabolism of virtually all
isoprenoids and it interconnects the 5-carbon moiety
isoprenoid synthesis with the mid- or long-chained com-
pound synthesis (Figure 1). In this study, the gene
PfFPPS as encoding a bifunctional FPPS/GGPPS enzyme
and its in vitro inhibition by risedronate were
characterized.
Figure 4 ESI-MS/MS analysis of the products synthesized by rPfFPPS. The in vitro enzymatic reaction was conducted as described in the
Methods section with non-radioactive substrates. In plates A, C and E show fragmentation spectra of GOH at m/z 81, 94 and 108, FOH at m/z 121,
134, 148 and 162 and GGOH at m/z 163, 189 and 217 standards. Plates B, D, and F illustrates matching diagnostic dissociation profiles for the
product of enzymatic reaction: GOH, FOH, GGOH.
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Figure 5 (See legend on next page.)
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In many organisms, the prenyltransferases that catalyze
chain elongation are highly selective for the chain length
of their products. The human genome contains genes for
two distinct monofunctional enzymes for GGPP and FPP
synthesis [34,35]. In the protozoans T. cruzi and P. vivax,
either FPPS or GGPPS is present, respectively [6,9]. On
the other hand, Artz et al. discuss the possibility that
GGPPS of P. vivax could be a bifunctional enzyme [9].
rPfFPPS expressed as a GST-fusion protein was used
to characterize its functional activity and to determine
the apparent kinetic parameters. Interestingly, the re-
moval of the GST tag from rPfFPPS resulted in almost
complete activity loss. An active form of GGPPS from
Thermus thermophilus and Sulfolobus acidocaldarius
was also overexpressed in E. coli cells as a GST fusion
protein. Ohto et al. suggested that the presence of the
GST-tag leads to thermal stability of the recombinant
enzymes [36].
Previous studies have shown that many FPPS homo-
logues can accept both DMAPP and GPP as allylic sub-
strates [37,38]. When synthesizing FPP from DMAPP,
the enzyme catalyzes two condensation reactions with
IPP, releasing only trace amounts of the intermediate
GPP [39], while GGPPS can accept DMAPP, GPP, and
FPP as substrates [40,41]. The activity of rPfFPPS and
the parasite extracts were confirmed by purification of
the synthesized products by RP-HPLC. When DMAPP
was used as a substrate, GPP was detected in minor
amounts while FPP and GGPP were the predominant
products. When the reaction was catalyzed with GPP as
allylic substrate, the only products observed were FPP
and GGPP. Accordingly, when FPP was used as sub-
strate, only GGPP was observed (Figure 3). No products
were detected when GGPP was used as a substrate.
Hence, rPfFPPS is a bifunctional FPPS/GGPPS enzyme.
Importantly, similar products were observed using a sec-
ond approach where alcoholic compounds were analysed
by TLC (Figure 2). Finally, the structures of products
GOH, FOH, and GGOH were confirmed by ESI-MS/MS
(Figure 4).
The bifunctional property of rPfFPPS in producing GGPP
as well as FPP was previously described only in three or-
ganisms: the archaebacterium M. thermoautotrophicum
[42], maize [43], and T. gondii [8]. A related enzyme was
described by Artz et al. in Cryptosporidium parvum.
Although this enzyme was annotated as an FPPS, it
shows the capacity to produce GGPP and also longer
polyisoprenes (up to 35 carbons) with the main prod-
ucts being C25 and C30-compounds with most of the
substrates tested [44]. This is indicative that the en-
zymes from P. falciparum and T. gondii have a rather
limited product spectrum compared to the Crypto-
sporidium homologue.
Amino acid sequence alignment of FPPS from differ-
ent organisms revealed conserved regions I to VII with
two characteristic aspartate rich motifs, one in region II
called FARM (first Asp-rich motif ) and in region VI
called SARM (second Asp-rich motif ). Wang and
Ohnuma [45] clearly demonstrated that the product
chain lengths of natural FPPS and GGPPS are mainly
regulated by the amino acid residues located at the
fourth and fifth position upstream of the FARM region.
These residues are at the bottom of the active site
pocket, making direct interactions with the ω-terminal
region of the allylic products. For this reason, the site
was designated the CLD (chain length determination) re-
gion. Usually, three possible amino acid substitutions are
described for the fourth and fifth amino acid positions
upstream the FARM region, and their identities deter-
mine the classification of FPPS and GGPPS: Type I FPPS
present aromatic amino acids residues on both positions;
Type II and Type III GGPPS present amino acid resi-
dues other than aromatic on both positions; Type II
FPPS and Type I GGPPS, as well as long chain prenyl
(See figure on previous page.)
Figure 5 RP-HPLC analysis of radiolabeled products biosynthesized by the native PfFPPS in 5 × 1010 semipurified Plasmodium
falciparum schizont stages. Extracts of parasites were obtained with methodology described by Tonhosolo et al. [10]. The reaction of [4-14C]IPP
with three allylic substrates: DMAPP, GPP, or FPP were realized. Arrows indicate the elution positions of isoprenoid standards. The retention times
of GPP, FPP and GGPP were identified by co-injection of commercial standards. (A) DMPP substrate, (B) GPP substrate, and (C) FPP substrate.
Table 1 Apparent kinetic constants for Plasmodium falciparum FPPS,(rPfFPPS)
Varied substrate Fixed substrate KM (μM) Vmax (nmol/min/mg)
DMAPP (0–150 μM) IPP 50 μM 68 ± 5 452.5 ± 16
GPP (0–50 μM) IPP 50 μM 7.8 ± 1.3 341 ± 19
FPP (0–50 μM) IPP 50 μM 2.06 ± 0.4 326.5 ± 16
IPP (0–80 μM) DMAPP 100 μM 2 ± 0.3 169 ± 5.4
IPP (0–80 μM) GPP 40 μM 0.81 ± 0.1 224 ± 3.4
IPP (0–50 μM) FPP 50 μM 2.4 ± 0.3 155.6 ± 4
Concentration ranges for each varied substrate are indicated. Activity versus varied substrate concentration plots are depicted on Additional file 4.
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synthases, present an aromatic amino acid residue solely
at the fifth position. Upon alignment of FPPS/GGPPS
from T. gondii and GGPPS from P. vivax it appears that
these proteins share more features with other FPPS as
already postulated by Ling et al. [8], and FPPS from P.
falciparum also falls in this cluster. Accordingly, these
enzymes show the apparent production of GGPP and
FPP, although this is not explicitly expressed in the
characterization of the P. vivax enzyme [9]. One may
argue that a hydrophilic side chain at the fifth amino
acid upstream of the FARM region plays a crucial role
for the production of both GGPP and FPP. Li et al. [46]
showed that the presence of a cysteine at the fifth pos-
ition is essential for the FPPS/GGPPS bifunctionality in
T. gondii. On the other hand, the methanobacterial ver-
sion of the enzyme contains a bulky phenylalanine at
this position and also produces GGPP and FPP [42],
turning evident that other regions may play a role in the
fine-specificity of product formation. Our analyses of the
CLD from 452 putative FPPS sequences show relatively
high sequence conservation of other amino acids close
to the FARM, and suggest the potential for the further
discovery of a number of FPPS/GGPPS bifunctionality in
organisms as diverse as animals, fungi, amoeba, plants,
and others. From the point of view of parasitism, it is
reasonable to infer that a bifunctional enzyme would be
a selective advantage. Considering the notoriously re-
duced genomes in parasitic organisms and the fact that
no other enzyme with similarity to known short chain
prenyl synthases has been identified in the currently se-
quenced Apicomplexa, this mutation has probably been
advantageous to these parasites given the essential
nature of both FPP and GGPP as precursors of a num-
ber of compounds important for many processes of their
cellular metabolism.
The results showed in TLC, HPLC, and ESI-MS/MS
(Figures 2, 3 and 4) are indicative of bifunctional activity
for rPfFPPS, showing catalytic activity with DMAPP,
GPP, and FPP as first substrates, ultimately yielding
GGPP as final product. Based on the conservation
among FPPS and GGPPS enzymes, it is tempting to sug-
gest that rPfFPPS mechanism of catalysis is bi-bi or-
dered, in which binding of either DMAPP, GPP, or FPP
to the free enzyme is followed by IPP binding. However,
other sequential or random mechanisms cannot be ruled
out for the P. falciparum enzyme since the results here
presented do not allow the determination of its kinetic
mechanism. A mandatory ordered kinetic mechanism
has been described for other FPPS, including the human
[47], T. cruzi [48], Staphylococcus aureus and E. coli [49]
homologues. According to such an ordered mechanism,
DMAPP or GPP binds to the free enzyme, with IPP hav-
ing larger binding affinity for the E:DMAPP or E:GPP
binary complexes [47]. Farnesyl synthesis by these FPPS
homologues is known to proceed through two subse-
quent steps. The reaction starts with the condensation
of one molecule of DMAPP and one molecule of IPP,
yielding the first product GPP. A second IPP molecule is
condensed with GPP to form FPP as the final product
[50]. Accordingly, P. falciparum bifunctional FPPS/
GGPPS catalysis is a three-step, four-substrate process
(Figure 1).
Data derived from activity assays of rPfFPPS were ap-
parently hyperbolic to all tested substrate pairs (Add-
itional file 4), suggesting that rPfFPPS follows MM
kinetics. As rPfFPPS catalyzes parallel and consecutive
reactions (Figure 1), the interpretation of the apparent
kinetic constants for this complex enzyme system is not
trivial (Table 1). The results presented here demonstrate
that rPfFPPS is capable of synthesizing GPP, FPP, and
GGPP from DMAPP and IPP (Figure 1, steps 1, 2 and
3); FPP and GGPP from GPP and IPP (Figure 1, steps 2
and 3); and GGPP from FPP and IPP (Figure 1, step 3).
Assuming that rPfFPPS follows an ordered mechanism
for substrate binding, when activity assays where carried
out in the presence of DMAPP and IPP, there will be
formation of GPP, followed by conversion of GPP to
form FPP, which will be competitive inhibitors of the re-
actions catalyzed in steps 1, 2, and 3, since DMAPP,
GPP, and FPP all compete for binding to the free enzyme
active site (Additional file 7). On the other hand,
rPfFPPS activity measurements using GPP and IPP as
substrates, there will be formation of FPP, which will be
competitive inhibitors of the reactions catalyzed in steps
2 and 3, since GPP and FPP compete for binding to free
enzyme. In this scenario, DMAPP, GPP, and FPP will
Figure 6 Expression of FPPS protein during the three stages of
the intra-erythrocytic cycle of Plasmodium falciparum using
parasites transfected. α-HA (antibody against the epitope of
haemagglutinin protein (HA), encoded fused to the protein of
interest-FPPS). Controls for the synchronization of intra-erythrocytic
stages of the parasite: α-pTEX150 (antibody against pTEX150, protein
constitutively present during the intra-erythrocytic cycle of the
parasite), α MSP2 (antibody against MSP2, protein present only in
the schizont stage). (R) ring trophozoite (T) trophozoite, (S) schizont.
Molecular size standards are indicated on the left (kDa).
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also behave as non-competitive inhibitors towards the
second substrate, IPP (Figure 1, steps 1, 2 and 3). This
same issue has been described for human FPPS [47],
where the authors clearly point out the difficulties of
mechanistic studies modelling and interpretation.
Evaluation of the apparent kinetic constants given in
Table 1 should thus be interpreted with caution. Except
for the substrate pair FPP/IPP (highlighted in bold), the
parameters presented for every other pair of substrates
correspond to overall dissociation constants (KM) and
overall Vmax values comprising the consecutive and par-
allel reactions that would be better described by modifi-
cations of the MM equation.
Similar KM values for substrate pair IPP/FPP were
reported for Homo sapiens GGPPS (3 ± 0.2 μM and 4.2
± 0.3 μM) [34] and P. vivax GGPPS (8.4 ± 1.6 μM and
7.3 ± 0.7 μM) [9]. The P. falciparum substrate pair IPP/
FPP also presented similar KM values, of 2.4 ± 0.3 μM
and 2.06 ± 0.4 μM (Table 1). The human FPPS enzyme
has also been characterized, and KM values for IPP/GPP
of 0.6 ± 0.1 μM and 0.7 ± 0.1 μM were reported [47].
Again P. falciparum data for substrate pair IPP/GPP in-
dicate similar KM for IPP (0.81 ± 0.1 μM) and almost ten
times larger KM value for GPP (7.8 ± 1.3 μM). These
values, however, correspond to global apparent constants
for steps 2 and 3 (Figure 1).
Considering varied substrates DMAPP, GPP, and FPP,
there appears to be a trend in MM constant values: KM
(FPP) < KM(GPP) < KM(DMAPP) (Table 1). Increased KM
values, without Vmax variations, are expected for reac-
tions catalyzed in the presence of competitive inhibitors
[22], as is the case for these substrates. No such KM vari-
ation is expected when IPP is the varied substrate as IPP
is a non-competitive inhibitor with respect to FPP, GPP,
and DMAPP. Non-competitive inhibitors are expected
to maintain KM values while decreasing Vmax values
[22]. These predictions appear to be borne out by the
data presented in Table 1.
Nitrogen-containing bisphosphonates like risedronate
are known to inhibit FPPS enzymes [11]. However, when
the activities of 26 different bisphosphonates against the
GGPPS protein from P. vivax were compared to their ef-
fect on P. falciparum in vitro growth, a poor correlation
was found [51]. Risedronate is commonly used in the
treatment of osteoporosis and it was shown that
risedronate has a significant inhibitory effect against
murine blood stage malaria [13], also inhibiting P. vivax
GGPPS [9], and human FPPS [47]. Jordão et al. showed
that risedronate presents inhibitory activity in vitro cul-
tures of P. falciparum, with an IC50 of 20 ± 1 μM, also
showed that risedronate inhibition is reversed by
addition of FPP or GGPP to the cultures, but not by the
addition of IPP [13]. These findings are in agreement
with the assumed competitive risedronate inhibition
towards FPP and GPP, and non-competitive inhibition
with respect to IPP.
As for the apparent kinetic constants reported in
Table 1, an IC50 value of 10 ± 1 μM for risedronate in-
hibition in the presence of GPP/IPP substrates also cor-
responds to a global inhibition value, in which both
risedronate and FPP product could account for the in-
hibitory activity. When risedronate effect was evaluated
in the presence of FPP/IPP as substrates, an IC50 value
of 1.3 ± 0.3 μM was estimated. The increased IC50 for
the rPfFPPS/GGPPS reaction catalyzed with GPP/IPP as
substrates is in agreement with the presence of an alter-
native substrate (FPP) as a competitive inhibitor [22]. A
similar IC50 value was reported for the inhibition of hu-
man FPPS activity by risedronate. When GPP/IPP were
used as substrates for FPPS enzyme activity measure-
ments, in which there is no alternative substrate present
in the reaction mixture, an IC50 value of 2.7 nM was de-
termined. On the other hand, when DMAPP/IPP were
the substrates, and reaction product GPP will also in-
hibit the enzyme along with risedronate, the IC50 value
increased to 3.2 nM [47]. The larger IC50 values of
risedronate in the presence of alternative substrates can
be a consequence of some of the enzyme active sites be-
ing occupied by these substrates thereby increasing the
concentration of inhibitor to achieve 50% of enzyme ac-
tivity inhibition. In addition, in vitro inhibition assays of
human FPPS also indicate that risedronate is a time
dependent slow tight-binding inhibitor, with lower IC50
values after incubation for 30 minutes of enzyme in the
presence of risedronate [47]. As described in the
Methods section, rPfFPPS formation of products was
evaluated only after 30 min incubation time, according
to Protocol I. This thus prevents time dependent fluctu-
ation of the IC50 value for the results presented here.
Nonetheless, an alternative assay may be necessary to
evaluate a possible tight-binding inhibition mechanism
for risedronate over rPfFPPS.
With evidence of risedronate being a competitive in-
hibitor towards GPP and FPP, its apparent Ki value was
estimated, according to Equation (3), as being equal to
1.96 μM (GPP/IPP) and 0.082 μM (FPP/IPP). Plasmo-
dium vivax GGPPS characterization studies reported an
apparent Ki value of 12.4 ± 1.7 μM, when using FPP/IPP
as substrates [9]; a value 151 times larger than the Ki
value reported in this work. Even though true Ki values
must be assigned before a more reliable comparison can
be made, P. falciparum FPPS/GGPPS seems to be more
prone to risedronate inhibition than its P. vivax
homologue. Reasoning for this finding is rather elusive
at the moment.
Gosh et al. have shown that risedronate or zoledronate
were not the most potent inhibitors in Plasmodium spp
[52]. They recently described a new generation of
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bisphosphonates known as “liphophilic biphosphonates”,
found to be more active against FPPS/GGPPS both
in vitro and in vivo than any other currently available
bisphosphonate [12]. In addition, No et al. demonstrated
that the lipophilic analogues of risedronate and
zolendronate had a stronger inhibitory activity against
GGPPS from P. vivax and also exhibited anti-malarial
activity in vitro and in vivo [53]. Although risedronate is
not a potent drug against P. falciparum, it was showed
by metabolic incorporation with [4-14C]IPP that
risedronate inhibits the biosynthesis of FPP and GGPP
and interferes with protein isoprenylation by inhibiting
the biosynthesis of FPP and GGPP, while also interferes
with the transfer of FPP to parasite proteins [13]. These
findings are in agreement with the view that risedronate
inhibits in vitro P. falciparum growth by inhibiting the
plasmodial FPPS. Importantly, it is expected that suc-
cessful inhibition of FPPS – a key enzyme between IPP/
DMAPP and all longer polyisoprenoids – exerts a
pleiotrophic effect on Plasmodium since it inhibits the
function of many important parasite proteins [10,54].
The rPfFPPS is expressed constitutively in all stages
during intra-erythrocytic cycle, demonstrated by using
transfected parasites with pFPPS-HA (Figure 6). FPP
and GGPP are substrates for prenyl:protein transferases
(farnesyl transferase and geranylgeranyl transferase),
catalyzing the post-translational modification of proteins
[55]. Previous studies have demonstrated that post-
translational modification of proteins occurs in all intra-
erythrocytic stage of P. falciparum, suggesting that the
enzyme is also active in all stages [55,56].
Conclusions
The rPfFPPS is a bifunctional enzyme, with FPPS/
GGPPS activity, producing FPP and GGPP. Both FPP
and GGPP occupy a central role leading to the synthesis
of important classes of compounds. These two com-
pounds were utilized for demonstrating the several iso-
prenoid biosynthesis pathway in P. falciparum [14].
Considering that: i) P. falciparum does not survive in
the absence of the IPP produced in the apicoplast unless
this precursor is supplemented [4]; ii) the FPPS/GGPPS
is the only enzyme leading to the precursors for the
synthesis of larger polyisoprenoids; and, iii) that FPPS/
GGPPS has major structural differences compared to
the human FPPS and GGPPS enzymes [43], this en-
zyme possibly represents an attractive drug target for
the development of selective inhibitors aiming the
erythrocytic stages of P. falciparum. The results
presented here and previously published data [13] on
risedronate inhibition in vitro and in vivo call for fur-
ther QSAR experiments for the development of more po-
tent bisphosphonate-based inhibitors selectivity targeting
this key point of the plasmodial isoprenoid metabolism.
Additional files
Additional file 1: Schematic representation of the integration of
rPfFPPs-HA in genomic locus. A) Diagram illustrating the integration
event by crossing-over and primers designed to detect this event (1, 2
and 3). Numbers 1 and 3 indicate the region where the primers have
been designed for detecting the integration of the gene in locus. B) PCR
detecting the integration of pFPP-HA in the genomic locus of P.
falciparum using primers 1 and 3. C) Detecting the control PCR
amplification of endogenous FPPS gene in both strains (transfected and
3D7) using the primers 1 and 2. (−) –negative control; (pFPPs-HA) –
transfected strain; (3D7) – wild type strain.
Additional file 2: Table of organisms, accession numbers, and CLD
region sequences analyzed. *Sequences characterized as bifunctional
FPP/GPPS are highlighted in gray and use bold font, *Excluded from CLD
analysis (X in red) were the sequences that either did not present the
canonical DDxxD FARM motif or had rare insertions (see main text).
Additional file 3: Expression of the rPfFPPS. SDS-polyacrylamide
gel 12% was stained with Coomassie Brilliant Blue. Lane 1, soluble
fraction from extract of E. coli BL21(DE3) pLys RIL/rPfFFPS; Lane 2, rPfFPPS
fused with GST; lane 3, GST. Molecular size standards are indicated on the
left (kDa).
Additional file 4: MM plots of the steady-state initial velocity
experiments for rPfFPPS/GGPPS. R2 values for each plot are: A) 0.99;
B) 0.99; C) 0.98; D) 0.99; E) 0.97; F) 0.99. Experiments and data analysis
were conducted as detailed under Methods, rPfFPPS kinetic assays
section. Concentration ranges of each varied substrate are depicted on
Table 1. Data were fitted to Equation (1).
Additional file 5: Inhibition of rPfFPPS/GGPPS activity by risedronate.
A) Substrate pair FPP/IPP (R2 = 0.98); B) Substrate pair GPP/IPP (R2 = 0.99).
rPfFPPS is expressed as its fractional activity; and risedronate concentrations
were plotted on log scale. Data were fitted to Equation (2).
Additional file 6: Sequence logo analysis of the chain-length
determination region. All sequences containing the canonical DDxxD
FARM motif were submitted to sequence logo analysis, as described in
the Methods section. Total height of each position reflects overall
sequence conservation at that column; height of each residue in a
column reflects its proportion in relation to other possible residues for
that column. Colors are for clarity, with aspartate in red, aromatic amino
acids in blue, serine and cysteine in cyan, and all other amino acids in
black.
Additional file 7: Proposed kinetic mechanism for rPfFPPS. GGPP
synthesis is proposed to follow a bi-bi ordered mechanism in an intricate
system of parallel and consecutive reactions.
Abbreviations
IPP: Isopentenyl diphosphate; DMAPP: Dimethylallyl diphosphate;
GPP: Geranyl diphosphate; FPP: Farnesyl diphosphate; GGPP: Geranylgeranyl
diphosphate; FPPS: Farnesyl diphosphate synthase; GGPPS: Geranylgeranyl
diphosphate synthase; N-BP: Nitrogen-containing bisphosphonate;
OPPS: Octaprenyl diphosphate synthase; rPfFPPS: P. falciparum FPPS; ESI-MS/
MS: Electrospray ionization tandem mass spectrometry; QSAR: Quantitative
structure–activity relationship models.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
FMJ initiated this work and performed most of the experiments, including
Figures 1, 2, 3, 4 and 5, Additional files 3 and 5 and wrote the majority of the
paper; HBG and MFdA performed the experiments in Figures 6 and
Additional file 1; JMPA performed computational studies (Additional files 2
and 6); CBA performed ESI-MS/MS analyses; TDB, AB and LAB contributed in
enzymatic kinetic analyses and wrote these aspects of paper. GW, EAK and
AMK supervised the project, analysed the data, wrote and reviewed the
paper before submission. All authors read and approved the final
manuscript.
Jordão et al. Malaria Journal 2013, 12:184 Page 13 of 15
http://www.malariajournal.com/content/12/1/184
Acknowledgements
FMJ is the recipient of a postgraduate fellowship from CNPq. HBG receives a
postgraduate fellowship from FAPESP. We thank S Wendel (Sírio Libanes
Hospital, NESTA) for providing the erythrocytes. We thank Danilo C Miguel
and Carsten Wrenger for critical reading of the manuscript and Valnice J
Peres for help with parasites preparation. This work was supported by grants
from CNPq and FAPESP (Brazil).
Author details
1Department of Parasitology, Institute of Biomedical Sciences, University of
São Paulo, Av. Lineu Prestes 1374, CEP 05508-000, São Paulo, SP, Brazil.
2Research Center for Molecular Biology and Functional, National Institute of
Science and Technology on Tuberculosis, Pontifical Catholic University of Rio
Grande do Sul, Rio Grande do Sul, Brazil. 3The Macfarlane Burnet Institute for
Medical Research and Public Health, Melbourne, Victoria, Australia.
Received: 22 March 2013 Accepted: 29 May 2013
Published: 4 June 2013
References
1. WHO: World Malaria Report. Geneva: World Health Organization; 2011.
2. WHO: Guidelines for the treatment of malaria. 2nd edition. Geneva: World
Health Organization; 2010.
3. Jomaa H, Wiesner J, Sanderbrand S, Altincicek B, Weidemeyer C, Hintz M,
Turbachova I, Eberl M, Zeidler J, Lichtenthaler HK, Soldati D, Beck E:
Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as
antimalarial drugs. Science 1999, 285:1573–1576.
4. Yeh E, DeRisi JL: Chemical rescue of malaria parasites lacking an
apicoplast defines organelle function in blood-stage Plasmodium
falciparum. PLoS Biol 2011, 9:e1001138.
5. Wang KC, Ohnuma S: Isoprenyl diphosphate synthases. Biochim Biophys
Acta 2000, 1529:33–48.
6. Montalvetti A, Bailey BN, Martin MB, Severin GW, Oldfield E, Docampo R:
Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl
pyrophosphate synthase. J Biol Chem 2001, 276:33930–33937.
7. Montalvetti A, Fernandez A, Sanders JM, Ghosh S, Van Brussel E, Oldfield E,
Docampo R: Farnesyl pyrophosphate synthase is an essential enzyme in
Trypanosoma brucei. In vitro RNA interference and in vivo inhibition
studies. J Biol Chem 2003, 278:17075–17083.
8. Ling Y, Li ZH, Miranda K, Oldfield E, Moreno SN: The farnesyl-diphosphate
/geranylgeranyl-diphosphate synthase of Toxoplasma gondii is a
bifunctional enzyme and a molecular target of bisphosphonates. J Biol
Chem 2007, 282:30804–30816.
9. Artz JD, Wernimont AK, Dunford JE, Schapira M, Dong A, Zhao Y, Lew J,
Russell RG, Ebetino FH, Oppermann U, Hui R: Molecular characterization of
a novel geranylgeranyl pyrophosphate synthase from Plasmodium
parasites. J Biol Chem 2011, 286:3315–3322.
10. Tonhosolo R, D'Alexandri FL, Genta FA, Wunderlich G, Gozzo FC, Eberlin MN,
Peres VJ, Kimura EA, Katzin AM: Identification, molecular cloning and
functional characterization of an octaprenyl pyrophosphate synthase in
intra-erythrocytic stages of Plasmodium falciparum. Biochem J 2005,
392:117–126.
11. Kavanagh KL, Guo K, Dunford JE, Wu X, Knapp S, Ebetino FH, Rogers MJ,
Russell RG, Oppermann U: The molecular mechanism of nitrogen-
containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci
USA 2006, 103:7829–7834.
12. Zhang Y, Cao R, Yin F, Hudock MP, Guo RT, Krysiak K, Mukherjee S, Gao YG,
Robinson H, Song Y, No JH, Bergan K, Leon A, Cass L, Goddard A, Chang TK,
Lin FY, Van Beek E, Papapoulos S, Wang AH, Kubo T, Ochi M, Mukkamala D,
Oldfield E: Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl
diphosphate synthase inhibitors: an X-ray and NMR investigation. J Am
Chem Soc 2009, 131:5153–5162.
13. Jordão FM, Saito AY, Miguel DC, Peres VP, Kimura EA, Katzin AM: In vitro
and in vivo antiplasmodial activities of risedronate and its interference
with protein prenylation in Plasmodium falciparum. Antimicrob Agents
Chemother 2011, 55:2026–2031.
14. Jordão FM, Kimura EA, Katzin AM: Isoprenoid biosynthesis in the
erythrocytic stages of Plasmodium falciparum. Mem Inst Oswaldo Cruz
2001, 106(Suppl 1):134–141.
15. Trager W, Jensen JB: Human malaria parasites in continuous culture.
Science 1976, 193:673–675.
16. Kimura EA, Couto AS, Peres VJ, Casal OL, Katzin AM: N-linked glycoproteins
are related to schizogony of the intraerythrocytic stage in Plasmodium
falciparum. J Biol Chem 1996, 271:14452–14461.
17. Trang DT, Huy NT, Kariu T, Tajima K, Kamei K: One-step concentration of
malarial parasite-infected red blood cells and removal of contaminating
white blood cells. Malar J 2004, 3:7.
18. Laemmli UK: Cleavage of structural proteins during the assembly of the
head of bacteriophage T4. Nature 1970, 227:680–685.
19. Bradford MM: A rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-dye
binding. Anal Biochem 1976, 72:248–254.
20. Chang TH, Guo RT, Ko TP, Wang AH, Liang PH: Crystal structure of type-III
geranylgeranyl pyrophosphate synthase from Saccharomyces cerevisiae
and the mechanism of product chain length determination. J Biol Chem
2006, 281:14991–15000.
21. Zhang D, Poulter CD: Analysis and purification of phosphorylated
isoprenoids by reversed-phase HPLC. Anal Biochem 1993, 213:356–361.
22. Copeland RA: Evaluation of enzyme inhibitors in drug discovery. A guide
for medicinal chemists and pharmacologists. Methods Biochem Anal 2005,
46:1–265.
23. Copeland RA: Reversible Inhibitors-Dose—Response Curves of enzyme
inhibition. In Enzymes–A practical introduction to structure, mechanism and
data analysis. Edited by Robert A. New York: Copeland Wiley-VCH Inc;
2000:266–304.
24. Cheng Y, Prusoff WH: Relationship between the inhibition constant (K1)
and the concentration of inhibitor which causes 50 per cent inhibition
(I50) of an enzymatic reaction. Biochem Pharmacol 1973, 22:3099–3108.
25. De Koning-Ward TF, Gilson PR: Keeping it simple: an easy method for
manipulating the expression levels of malaria proteins. Trends Parasitol
2009, 25:4–7.
26. Wu Y, Sifri CD, Lei HH, Su XZ, Wellems TE: Transfection of Plasmodium
falciparum within human red blood cells. Proc Natl Acad Sci USA 1995,
92:973–977.
27. Fidock DA, Wellems TE: Transformation with human dihydrofolate
reductase renders malaria parasites insensitive to WR99210 but does
not affect the intrinsic activity of proguanil. Proc Natl Acad Sci USA 1997,
94:10931–10936.
28. Ljungdtröm I, Schlichtherle M, Scherf A, Wahlgren M: Methods in Malaria
Research. Virginia: Manassas; 2004.
29. Bullen HE, Tonkin CJ, O'Donnell RA, Tham WH, Papenfuss AT, Gould S,
Cowman AF, Crabb BS, Gilson PR: A novel family of Apicomplexan
glideosome-associated proteins with an inner membrane-anchoring
role. J Biol Chem 2009, 284:25353–25363.
30. Hawthorne PL, Trenholme KR, Skinner-Adams TS, Spielmann T, Fischer K,
Dixon MW, Ortega MR, Anderson KL, Kemp DJ, Gardiner DL: A novel
Plasmodium falciparum ring stage protein, REX, is located in Maurer's
clefts. Mol Biochem Parasitol 2004, 136:181–189.
31. Gerold P, Schofield L, Blackman MJ, Holder AA, Schwarz RT: Structural
analysis of the glycosyl-phosphatidylinositol membrane anchor of the
merozoite surface proteins-1 and −2 of Plasmodium falciparum. Mol
Biochem Parasitol 1996, 75:131–143.
32. Edgar RC: MUSCLE: multiple sequence alignment with high accuracy and
high throughput. Nucleic Acids Res 2004, 32(5):1792–1797. 2004 Mar 19,
PMID: 15034147.
33. Crooks GE, Hon G, Chandonia JM, Brenner SE: WebLogo: a sequence logo
generator. Genome Res 2004, 14(6):1188–1190. 2004 Jun, PMID: 15173120.
34. Kavanagh KL, Dunford JE, Bunkoczi G, Russell RG, Oppermann U: The crystal
structure of human geranylgeranyl pyrophosphate synthase reveals a
novel hexameric arrangement and inhibitory product binding. J Biol
Chem 2006, 281:22004–22012.
35. Ding VD, Sheares BT, Bergstrom JD, Ponpipom MM, Perez LB, Poulter CD:
Purification and characterization of recombinant human farnesyl
diphosphate synthase expressed in Escherichia coli. Biochem J 1991,
275(Pt 1):61–65.
36. Ohto C, Nakane H, Hemmi H, Ohnuma S, Obata S, Nishino T:
Overexpression of an archaeal geranylgeranyl diphosphate synthase in
Escherichia coli cells. Biosci Biotechnol Biochem 1998, 62:1243–1246.
37. Reed BC, Rilling HC: Crystallization and partial characterization of
prenyltransferase from avian liver. Biochemistry 1975, 14:50–54.
38. Reed BC, Rilling HC: Substrate Binding of avian liver prenyltransferase.
Biochemistry 1976, 15:3739–3745.
Jordão et al. Malaria Journal 2013, 12:184 Page 14 of 15
http://www.malariajournal.com/content/12/1/184
39. Ishii K, Sagami H, Ogura K: A novel prenyltransferase from Paracoccus
denitrificans. Biochem J 1986, 233:773–777.
40. Hefner J, Ketchum RE, Croteau R: Cloning and functional expression of a
cDNA encoding geranylgeranyl diphosphate synthase from Taxus
canadensis and assessment of the role of this prenyltransferase in cells
induced for taxol production. Arch Biochem Biophys 1998, 360:62–74.
41. Wang G, Dixon RA: Heterodimeric geranyl(geranyl)diphosphate
synthase from hop (Humulus lupulus) and the evolution of
monoterpene biosynthesis. Proc Natl Acad Sci USA 2009, 106:9914–9919.
42. Chen A, Poulter CD: Purification and characterization of farnesyl
diphosphate/geranylgeranyl diphosphate synthase. A thermostable
bifunctional enzyme from Methanobacterium thermoautotrophicum.
J Biol Chem 1993, 268:11002–11007.
43. Cervantes-Cervantes M, Gallagher CE, Zhu C, Wurtzel ET: Maize cDNAs
expressed in endosperm encode functional farnesyl diphosphate
synthase with geranylgeranyl diphosphate synthase activity.
Plant Physiol 2006, 141:220–231.
44. Artz JD, Dunford JE, Arrowood MJ, Dong A, Chruszcz M, Kavanagh KL,
Minor W, Russell RG, Ebetino FH, Oppermann U, Hui R: Targeting a
uniquely nonspecific prenyl synthase with bisphosphonates to
combat cryptosporidiosis. Chem Biol 2008, 15:1296–1306.
45. Wang K, Ohnuma S: Chain-length determination mechanism of isoprenyl
diphosphate synthases and implications for molecular evolution.
Trends Biochem Sci 1999, 24:445–451.
46. Li Z, Cintrón R, Koon NA, Moreno SNJ: The N-terminus and the chain
length determination domain play a role in the length of the isoprenoid
product of the bifunctional Toxoplasma gondii farnesyl diphosphate
synthase. Biochemistry 2012, 51:7533–7540.
47. Glickman JF, Schmid A: Farnesyl pyrophosphate synthase: real-time
kinetics and inhibition by nitrogen-containing bisphosphonates in a
scintillation assay. Assay Drug Dev Technol 2007, 5:205–214.
48. Sigman L, Sanchez VM, Turjanski AG: Characterization of the farnesyl
pyrophosphate synthase of Trypanosoma cruzi by homology modeling
and molecular dynamics. J Mol Graph Model 2006, 25:345–352.
49. Sanchez VM, Crespo A, Gutkind JS, Turjanski AG: Investigation of the
catalytic mechanism of farnesyl pyrophosphate synthase by computer
simulation. J Phys Chem B 2006, 110:18052–18057.
50. Ashby MN, Edwards PA: Identification and regulation of a rat liver cDNA
encoding farnesyl pyrophosphate synthetase. J Biol Chem 1989, 264:635–640.
51. Mukkamala D, No JH, Cass LM, Chang TK, Oldfield E: Bisphosphonate
inhibition of a Plasmodium farnesyl diphosphate synthase and a
general method for predicting cell-based activity from enzyme data.
J Med Chem 2008, 51:7827–7833.
52. Ghosh S, Chan JM, Lea CR, Meints GA, Lewis JC, Tovian ZS, Flessner RM,
Loftus TC, Bruchhaus I, Kendrick H, Croft SL, Kemp RG, Kobayashi S,
Nozaki T, Oldfield E: Effects of bisphosphonates on the growth of
Entamoeba histolytica and Plasmodium species in vitro and in vivo.
J Med Chem 2004, 47:175–187.
53. No JH, De Macedo DF, Zhang Y, Liu YL, Zhu W, Feng X, Yoo JA, Lee E,
Wang K, Hui R, Freitas-Junior LH, Oldfield E: Lipophilic analogs of
zoledronate and risedronate inhibit Plasmodium geranylgeranyl
diphosphate synthase (GGPPS) and exhibit potent antimalarial
activity. Proc Natl Acad Sci USA 2012, 109:4058–4063.
54. Tonhosolo R, D'Alexandri FL, De Rosso VV, Gazarini ML, Matsumura MY,
Peres VJ, Merino EF, Carlton JM, Wunderlich G, Mercadante AZ, Kimura EA,
Katzin AM: Carotenoid biosynthesis in intraerythrocytic stages of
Plasmodium falciparum. J Biol Chem 2009, 284:9974–9985.
55. Chakrabarti D, Da Silva T, Barger J, Paquette S, Patel H, Patterson S,
Allen CM: Protein farnesyltransferase and protein prenylation in
Plasmodium falciparum. J Biol Chem 2002, 277:42066–42073.
56. Moura IC, Wunderlich G, Uhrig ML, Couto AS, Peres VJ, Katzin AM,
Kimura EA: Limonene arrests parasite development and inhibits
isoprenylation of proteins in Plasmodium falciparum. Antimicrob Agents
Chemother 2001, 45:2553–2558.
doi:10.1186/1475-2875-12-184
Cite this article as: Jordão et al.: Cloning and characterization of
bifunctional enzyme farnesyl diphosphate/geranylgeranyl diphosphate
synthase from Plasmodium falciparum. Malaria Journal 2013 12:184.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Jordão et al. Malaria Journal 2013, 12:184 Page 15 of 15
http://www.malariajournal.com/content/12/1/184
